Short Bowel Syndrome Market Growth Forecast With Analysis Of Industry Progress Through 2030

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Forecasted Rise In Market Size Of The Short Bowel Syndrome Market During The Forecast Period?

The market size for short bowel syndrome has experienced rapid expansion in recent years. It is forecast to rise from $3.08 billion in 2025 to $3.53 billion in 2026, at a compound annual growth rate (CAGR) of 14.6%. This historical growth stemmed from various factors, including the increasing prevalence of short bowel syndrome, historically limited treatment options, reliance on parenteral nutrition, a rise in gastrointestinal surgeries, and growing hospital awareness.

The market size for short bowel syndrome is poised for substantial expansion over the upcoming years. It is projected to reach $6.02 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.2%. This growth during the forecast period can be attributed to factors such as the development of innovative therapeutics, enhanced accessibility to home infusion services, the implementation of personalized treatment approaches, the integration of microbiome therapies, and an increase in clinical trials for SBS interventions. Significant trends expected in the forecast period encompass a rise in parenteral nutrition solutions, intensified development of intestinal rehabilitation therapies, the adoption of new surgical interventions, a heightened focus on gut microbiome modulation, and the expansion of patient support programs.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23515&type=smp

What Important Drivers Are Powering The Short Bowel Syndrome Market Growth?

The rising occurrence of gastrointestinal diseases is expected to drive the growth of the short bowel syndrome market in the future. Gastrointestinal diseases encompass a wide array of conditions impacting the digestive system, including disorders affecting the stomach, intestines, liver, and pancreas, often leading to compromised digestion and nutrient absorption. The expanding prevalence of gastrointestinal diseases is primarily fueled by unhealthy dietary patterns that disrupt gut health and promote inflammation. These diseases can contribute to the development of short bowel syndrome by necessitating the surgical removal of damaged intestinal segments, which results in reduced absorptive capacity. For example, in September 2023, data from the Inflammatory Bowel Disease (IBD) Clinical and Research Centre, a Canada-based organization focused on improving the lives of patients with Crohn’s disease and ulcerative colitis, indicated that over 320,000 people in Canada have inflammatory bowel disease (IBD), with a prevalence of 825 per 100,000 in 2023. As the prevalence is projected to increase by 2.44% annually, it is estimated that 1.1% of the population, or 470,000 Canadians, will be living with IBD by 2035. Thus, the increasing prevalence of gastrointestinal diseases is a significant driver for the short bowel syndrome market’s expansion.

What Key Segment Areas Are Included In The Short Bowel Syndrome Market Assessment?

The short bowel syndrome market covered in this report is segmented –

1) By Type: Glucagon-Like Peptide (GLP-2), Growth Hormone, Glutamine

2) By Diagnosis: Physical Exam, Blood Tests, Fecal Fat Tests, Imaging Procedures, Other Diagnosis

3) By Treatment: Nutritional Therapy, Medications, Surgery, Transplant

4) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Other Distribution Channels

Subsegments:

1) By Glucagon-Like Peptide (GLP-2): Teduglutide, Other GLP-2 Analogues

2) By Growth Hormone: Somatropin, Other Growth Hormone Therapies

3) By Glutamine: Oral Glutamine, Intravenous Glutamine

Which Trends Are Expected To Shape The Short Bowel Syndrome Market?

Leading companies within the sexually transmitted infections (STIs) market are creating advanced products utilizing fluorescent PCR technology to secure a competitive edge. Fluorescent PCR (Polymerase Chain Reaction) technology, a molecular biology technique, is employed for the detection and quantification of particular DNA sequences within biological samples. As an example, in March 2023, Jiangsu Bioperfectus Technologies Co. Ltd., a Chinese molecular diagnostic solutions provider, launched two new polymer chain reaction (PCR) kits: the Mycoplasma Hominis Real-Time PCR Kit and the Treponema Pallidum Real-Time PCR Kit. These kits offer a comprehensive PCR solution for the early identification of sexually transmitted illnesses, which affect a significant number of people. The BioPerfectus Mycoplasma Hominis Real-Time PCR Kit is a reagent designed to detect Mycoplasma hominis in human male urethral swabs, female cervical or vaginal swabs, and urine samples using fluorescent PCR technology. Conversely, the BioPerfectus Treponema Pallidum Real-Time PCR Kit aims to identify treponema pallidum nucleic acid in human serum and plasma.

Which Firms Are Competing In The Short Bowel Syndrome Market?

Major companies operating in the short bowel syndrome market are Nestlé SA, Pfizer Inc, Johnson & Johnson, Sanofi SA, Nutrinia, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Zealand Pharma, Baxter International Inc., OPKO Health Inc, Ironwood Pharmaceuticals Inc., Hanmi Pharm Co Ltd, Emmaus Life Sciences Inc, Jaguar Health, 9 Meters Biopharma Inc, OxThera Inc, EnteraBio Ltd, GLyPharma Therapeutic Inc, Fresenius Kabi AG, Danone S A, B Braun Melsungen AG, Medtronic plc

Access The Complete Short Bowel Syndrome Market Report:

https://www.thebusinessresearchcompany.com/report/short-bowel-syndrome-global-market-report

Which Region Stands As The Largest Contributor To The Short Bowel Syndrome Market?

North America was the largest region in the short bowel syndrome market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short bowel syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Short Bowel Syndrome Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=23515&type=smp

Browse Through More Reports Similar to the Global Short Bowel Syndrome Market 2026, By The Business Research Company

Bowel Management Systems Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/bowel-management-systems-global-market-report

Inflammatory Bowel Disease Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

Ulcerative Colitis Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/ulcerative-colitis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795